Clinical trial
Clinical Trial of Docetaxel in Combination With Gemcitabine in…
NCT00183794 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00183794 |
|---|---|
| Title | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma |
| Official title | Phase II Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Aventis Pharmaceuticals Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Carcinoma, Peritoneal Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel and Gemcitabine |
| Enrollment | 20 |
| Start date | Nov 1, 2002 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2010 |
| First posted | Sep 16, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: